The systemic angiotensin-II role in the development of retinopathy of prematurity
https://doi.org/10.21516/2072-0076-2023-16-2-63-66
Abstract
Purpose: to determine the role of the systemic angiotensin II (AT-II) in the pathogenesis of retinopathy of prematurity (ROP) and assess its prognostic value.
Material and methods. 34 premature infants at risk of developing ROP were examined according to the ophthalmological ROP screening protocol adopted in the Russian Federation. Retrospectively, the infants were divided into 2 groups: those without ROP (n = 15) and those with developed ROP (n = 19). The average gestational age of those without ROP was 28.12 ± 0.64 weeks, their average body weight at birth was 1164 ± 118.6 g. The respective values for the group with ROP were 27.8 ± 0.6 weeks and 1142.6 ± 108.4 g. The two groups had similar extent of general somatic burden. At 32–35 weeks and 36–39 weeks of post-conceptual age (PCA), the infants of both groups were tested for the concentration of AT-II in blood serum using the enzyme-linked immunosorbent assay (ELISA).
Results: on the 32–35 week of PCA, the average level of AT-II in blood serum of premature infants of the ROP group was significantly increased as compared to that of the non-ROP group (p = 0.03), while on the 36–39 week of PCA no statistically significant difference between the AT-II levels in the examined groups was found (p = 0.73).
Conclusion. We established that the systemic AT-II level has a trigger role in the development of ROP. A high level of this parameter found at the onset of ROP can be considered as an early prognostic criterion for the risk of ROP development.
About the Authors
N. A. Osipova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Nataly A. Osipova, Cand. of Med. Sci., researcher, department of eye diseases of children,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
N. B. Chesnokova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Nataly B. Chesnokova, Dr. of Biol. Sci., professor, chief researcher, department of pathophysiology and biochemistry,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
L. A. Katargina
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Lyudmila A. Katargina, Dr. of Med. Sci., professor, deputy director, head of the department of eye diseases of children,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
T. A. Pavlenko
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Tatiana A. Pavlenko, Cand. of Med. Sci., head of the department of pathophysiology and biochemistry,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
O. V. Beznos
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Olga V. Beznos, researcher, department of pathophysiology and biochemistry,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
A. Yu. Panova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Anna Yu. Panova, junior researcher, department of eye diseases of children,
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
References
1. Nath M, Chandra P, Halder N, Singh B, et al. Involvement of renin-angiotensin system in retinopathy of prematurity - A possible target for therapeutic intervention. PLoS One. 2016; 11 (12): e0168809. doi: 10.1371/journal.pone.0168809
2. Yaguchi S, Ogawa Y, Shimmura S, et al. Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease. PLoS One. 2013; 8 (6): e64724. doi: 10.1371/journal.pone.0064724
3. Sramek SJ, Wallow IH, Day RP, Ehrlich EN. Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci. 1988; 29 (11): 1749–52.
4. Wagner J, Jan Danser AH, Derkx FH, et al. Demonstration of renin mRNA, angiotensinogen m RNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for the intraocular renin angiotensin system. Br J Ophthalmol. 1996; 80: 159–63. doi: 10.1136/bjo.80.2.159
5. Senanayake Pd, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007; 48 (7): 3301–11. doi: 10.1167/iovs.06-1024
6. Ramirez M, Davidson EA, Luttenauer L, et al. The renin-angiotensin system in the rabbit eye. J Ocul Pharmacol Ther. 1996; 12 (3): 299–312. doi: 10.1089/jop.1996.12.299
7. Sarlos S, Wilkinson-Berka JL. The renin-angiotensin system and the developing retinal vasculature. Invest Ophthalmol Vis Sci. 2005; 46 (3): 1069–77. doi: 10.1167/iovs.04-0885
8. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammationrelated pathways. Lab Invest. 2002; 82 (6): 747–56. doi: 10.1097/01.lab.0000017372.76297.eb
9. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998; 83 (3): 233–40. doi: 10.1161/01.res.83.3.233
10. Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond). 2013; 124 (10): 597–615. doi: 10.1042/CS20120212
11. Ola MS, Alhomida AS, Ferrario CM, Ahmad S. Role of tissue renin-angiotensin system and the chymase/angiotensin-(1-12) axis in the pathogenesis of diabetic retinopathy. Curr Med Chem. 2017; 24 (28): 3104–14. doi:10.2174/0929867324666170407141955.
12. Katargina L.A., Chesnokova N.B., Beznos O.V., Osipova N.A., Panova A.Yu. Angiotensin-II as a trigger factor in the development of retinopathy of prematurity. Ophthalmology in Russia. 2020; 17 (4): 746–51 (In Russ.). doi: https://doi.org/10.18008/1816-5095-2020-4-746-751
13. Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia. 2000; 43 (11): 1360–7. doi: 10.1007/s001250051539
14. Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia. 2008; 56 (10): 1076–90. doi: 10.1002/glia.20680
15. Sarlos S, Rizkalla B, Moravski CJ, et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003; 163 (3): 879–87. doi: 10.1016/S0002-9440(10) 63448-7
16. Hård A-L, Wennerholm U-B, Niklasson A, Hellström A. Severe ROP in twins after blockage of the renin-angiotensin system during gestation. Acta Paediatr. 2008; 97 (8): 1142–4. doi: 10.1111/j.1651-2227.2008.00851.x
Review
For citations:
Osipova N.A., Chesnokova N.B., Katargina L.A., Pavlenko T.A., Beznos O.V., Panova A.Yu. The systemic angiotensin-II role in the development of retinopathy of prematurity. Russian Ophthalmological Journal. 2023;16(2):63-66. (In Russ.) https://doi.org/10.21516/2072-0076-2023-16-2-63-66
Views:
283
Email this article 